Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides.
Carboxyalkyl peptides containing a biphenylylethyl group at the P1' position were found to be potent inhibitors of stromelysin-1 (MMP-3) and gelatinase A (MMP-2), in the range of 10-50 nM, but poor inhibitors of collagenase (MMP-1). Combination of a biphenylylethyl moiety at P1', a tert-butyl group at P2', and a methyl group at P3' produced orally bioavailable inhibitors as measured by an in vivo model of MMP-3 degradation of radiolabeled transferrin in the mouse pleural cavity. The X-ray structure of a complex of a P1-biphenyl inhibitor and the catalytic domain of MMP-3 is described. Inhibitors that contained halogenated biphenylylethyl residues at P1' proved to be superior in terms of enzyme potency and oral activity with 2(R)-[2-(4'-fluoro-4-biphenylyl)ethyl]-4(S)-n-butyl-1,5-pentane dioic acid 1-(alpha(S)-tert-butylglycine methylamide) amide (L-758,354, 26) having a Ki of 10 nM against MMP-3 and an ED50 of 11 mg/kg po in the mouse pleural cavity assay. This compound was evaluated in acute (MMP-3 and IL-1 beta injection in the rabbit) and chronic (rat adjuvant-induced arthritis and mouse collagen-induced arthritis) models of cartilage destruction but showed activity only in the MMP-3 injection model (ED50 = 6 mg/kg iv).
Esser
C K
CK
Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, New Jersey 07065-0900, USA.
Bugianesi
R L
RL
Caldwell
C G
CG
Chapman
K T
KT
Durette
P L
PL
Girotra
N N
NN
Kopka
I E
IE
Lanza
T J
TJ
Levorse
D A
DA
MacCoss
M
M
Owens
K A
KA
Ponpipom
M M
MM
Simeone
J P
JP
Harrison
R K
RK
Niedzwiecki
L
L
Becker
J W
JW
Marcy
A I
AI
Axel
M G
MG
Christen
A J
AJ
McDonnell
J
J
Moore
V L
VL
Olszewski
J M
JM
Saphos
C
C
Visco
D M
DM
Hagmann
W K
WK
D000818:Animals; D001168:Arthritis / Q000188:drug therapy; D001665:Binding Sites; D002356:Cartilage / Q000187:drug effects; D018360:Crystallography, X-Ray; D004151:Dipeptides / Q000138:chemical synthesis / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D004195:Disease Models, Animal; D018093:Gelatinases / Q000037:antagonists & inhibitors; D007375:Interleukin-1 / Q000008:administration & dosage / Q000494:pharmacology; D009682:Magnetic Resonance Spectroscopy; D020781:Matrix Metalloproteinase 1; D020778:Matrix Metalloproteinase 2; D061965:Matrix Metalloproteinase Inhibitors; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors; D051379:Mice; D008958:Models, Molecular; D015394:Molecular Structure; D011480:Protease Inhibitors / Q000138:chemical synthesis / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D011817:Rabbits; D051381:Rats; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors; D013329:Structure-Activity Relationship; D014168:Transferrin / Q000378:metabolism; D015032:Zinc / Q000737:chemistry / Q000378:metabolism
D004151:Dipeptides; D007375:Interleukin-1; C105326:L 758354; D061965:Matrix Metalloproteinase Inhibitors; D011480:Protease Inhibitors; D011994:Recombinant Proteins; D014168:Transferrin; C085083:N-(1-carboxyethyl)-alpha-(2-phenylethyl)glycyl-leucine, N-phenylamide; D018093:Gelatinases; D008666:Metalloendopeptidases; D020778:Matrix Metalloproteinase 2; D020781:Matrix Metalloproteinase 1; D015032:Zinc